Prospectively, the SUREK-mediated vaccination effect might also be tested in a less immunogenic GD2-expressing neuroblastoma mouse model with a murine TH-MYCN transgenic neuroblastoma cell line (9464D-GD2) established by Voeller et al. The gene discussed is MYCN; the disease is neuroblastoma.